Document is current
Any future updates will be listed below
-
Authors
Ye, Jian https://orcid.org/0000-0002-6955-9262
Qin, Shuyang S
Hughson, Angela L
Hannon, Gary https://orcid.org/0000-0003-1204-0299
Salama, Noah A
Vrooman, Tara G
Lesch, Maggie L
Lesser, Sidney
Eckl, Sarah L
Jewell, Rachel
Benoodt, Lauren
Mills, Bradley N
Johnston, Carl J
Lord, Edith
Belt, Brian A
Calvi, Laura M
Linehan, David
Luheshi, Nadia
Eyles, Jim
Gerber, Scott A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04999969 at ClinicalTrials.govDocuments that mention this clinical trial
704 AZD0171 (αLIF) in combination with chemotherapy and αPDL1 alters myeloid and cancer associated fibroblast (CAF) phenotype in the tumour microenvironment (TME) in preclinical models
https://doi.org/10.1136/jitc-2024-sitc2024.0704
Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models
https://doi.org/10.1136/jitc-2024-010820
785 mAZD0171 mediated LIF blockade in combination with chemotherapy and PD-L1 inhibition repolarizes macrophages and increases T cell infiltration via CX3CR1-CX3CL1 axis
https://doi.org/10.1136/jitc-2023-sitc2023.0785
Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy
https://doi.org/10.1136/jitc-2024-009702
-
Funding
Funding for this research was provided by:
NIH (R01CA168863)
NIH (R01CA230277)
NIH (R01CA236390)
NIH (R01CA262580)
AstraZeneca (N/A)
- License Information
